CCL6 and CCL9 are not sufficient to induce full protection against a BCR-ABL–induced leukemia. (A) RT-PCR showing BCR-ABL, CCL9, and CCL6 expression in the BaF3 cells injected into mice. (B) CCL6 and CCL9 cannot substitute for ICSBP in conferring immune protection from leukemia. Survival curves for 6- to 9-week-old Balb/c mice injected with 0.3 × 10⁶ BaF3 cells expressing BCR-ABL alone (×), or together with 0.15 × 10⁶ BaF3 cells expressing CCL6 and 0.15 × 10⁶ BaF3 cells expressing CCL9 (△). Experiment was repeated 3 times, with n = 15 for each condition. Unpaired t test shows significance at P < .003 for differences in survival curves. (C) CCL6 and CCL9 promote survival only in immunocompetent mice. Survival curves obtained for 9- to 12-week-old Rag 2^−/− mice injected with 3 × 10⁵ BaF3 cells expressing BCR-ABL alone (×) or together with 3 × 10⁵ BaF3 cells expressing CCL6 and 3 × 10⁵ BaF3 cells expressing CCL9 (△). N = 10 for each condition.